EGFR and non-small cell lung carcinoma: Concerning different generation EGFR-TKIs, clinical trials of LUX-Lung 7 and ARCHER-1050 both showed second-generation (afatinib and dacomitinib) EGFR-TKIs significantly improved PFS more so than first-generation (gefitinib) EGFR-TKIs in EGFR-mutant NSCLC patients10,11.